Navigation Links
Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
Date:8/3/2010

tial value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales forces; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our licensing transactions, our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to enter into collaboration or other license arrangements with respect to our technology on commercially reasonable terms or at all, our ability to satisfy FDA and other regulatory requirements and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 4, 2010 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments th
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
2. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
3. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
4. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
5. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
6. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
7. Cornerstone Therapeutics Announces Management Change
8. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
9. Cornerstone Therapeutics Announces Collaboration with The Cough Company
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... MiMedx Group, Inc. (OTC Bulletin Board: MDXG.OB) announced today ... Shield(TM). In April 2009, The Food and Drug Administration ... vessels following anterior vertebral surgeries. The Vaso Shield is ... and patent applications, as well as a proprietary manufacturing process. ...
... Sciences, Inc., a privately held biopharmaceutical company that specializes in ... reported top-line results from the month 24 readout of the ... Phase 3 pivotal clinical trials (Trial A and Trial B) ... macular edema (DME). The primary efficacy endpoint for the FAME ...
Cached Medicine Technology:MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 2MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device 3Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 2Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 3Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 4Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 5Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 6
(Date:4/18/2014)... The Gerontologist reports that among ... a decrease in anxiety about death and increases in ... lives. In particular, listening to gospel music is associated ... increase in sense of control. , These associations are ... individuals of both low- and high-socioeconomic status. , The ...
(Date:4/18/2014)... Medicine researchers have been awarded two-year grants for their ... this month. Of the 110 initial submissions to the ... Program, only four projects were funded, three of which ... Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias ... of oncology, will use his $500,000 proof of principle ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2
... probability of tumor response ... and accelerates drug development, SEATTLE, Oct. ... Systems Medicine, LLC (SM), a,wholly-owned subsidiary of CTI, today announced ... trial of brostallicin used in combination,with either bevacizumab or irinotecan, ...
... results include 19 percent sales growth and EPS of $.85, Q3 pro forma adjusted results ... ... EPS guidance updated to $3.50 - $3.55, or ... $2.76 - $2.81 reported, INDIANAPOLIS, Oct. 18 Eli Lilly and Company,(NYSE: LLY ) ...
... Consecutive Quarter, DEERFIELD, Ill., Oct. 18 Baxter ... results for the period,ended September 30, 2007 and raised ... quarter net income of $395 million increased 6 percent ... 2006. Net earnings per,diluted share of $0.61 increased 7 ...
... Blood Pressure Cuff and Weight Scale Added to Our ... Telemedicine Product ... Sheets: XMDC) announced the company has added two new,Bluetooth(R) enabled telemedicine ... care, hospitals, long term care,facilities, and physician groups. "The addition ...
... More than half of holiday shoppers (57,percent) plan ... good cause*. This,year, choose a gift that will brighten ... the seventh leading cause of death,in the United States. ... families struggling with,Alzheimer,s or support innovative research grants, which ...
... Inc. (NASDAQ:QLTI;,TSX:QLT) today reported that Novartis AG announced ... million for the quarter ended,September 30, 2007. This ... the,third quarter of 2006 and a 17.9% decline ... in the U.S. for the quarter were approximately ...
Cached Medicine News:Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 2Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 3Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 4Health News:Lilly Delivers Strong Third-Quarter Results 2Health News:Lilly Delivers Strong Third-Quarter Results 3Health News:Lilly Delivers Strong Third-Quarter Results 4Health News:Lilly Delivers Strong Third-Quarter Results 5Health News:Lilly Delivers Strong Third-Quarter Results 6Health News:Lilly Delivers Strong Third-Quarter Results 7Health News:Lilly Delivers Strong Third-Quarter Results 8Health News:Lilly Delivers Strong Third-Quarter Results 9Health News:Lilly Delivers Strong Third-Quarter Results 10Health News:Lilly Delivers Strong Third-Quarter Results 11Health News:Lilly Delivers Strong Third-Quarter Results 12Health News:Lilly Delivers Strong Third-Quarter Results 13Health News:Lilly Delivers Strong Third-Quarter Results 14Health News:Lilly Delivers Strong Third-Quarter Results 15Health News:Lilly Delivers Strong Third-Quarter Results 16Health News:Lilly Delivers Strong Third-Quarter Results 17Health News:Lilly Delivers Strong Third-Quarter Results 18Health News:Lilly Delivers Strong Third-Quarter Results 19Health News:Baxter Reports Strong Third Quarter Sales and Earnings 2Health News:Baxter Reports Strong Third Quarter Sales and Earnings 3Health News:Baxter Reports Strong Third Quarter Sales and Earnings 4Health News:Baxter Reports Strong Third Quarter Sales and Earnings 5Health News:Baxter Reports Strong Third Quarter Sales and Earnings 6Health News:Baxter Reports Strong Third Quarter Sales and Earnings 7Health News:Baxter Reports Strong Third Quarter Sales and Earnings 8Health News:Baxter Reports Strong Third Quarter Sales and Earnings 9Health News:Baxter Reports Strong Third Quarter Sales and Earnings 10Health News:Baxter Reports Strong Third Quarter Sales and Earnings 11Health News:Baxter Reports Strong Third Quarter Sales and Earnings 12Health News:Baxter Reports Strong Third Quarter Sales and Earnings 13Health News:Baxter Reports Strong Third Quarter Sales and Earnings 14Health News:Baxter Reports Strong Third Quarter Sales and Earnings 15
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
... QuantiGene 2.0 is a reagent and ... expression knockdown. The high throughput plate based ... assay that provides a unique approach for ... reporter signal using branched DNA (bDNA) technology. ...
Xsera Rapid HIV-1/2 Antibody Controls are unassayed positive and negative quality control materials used for monitoring the performance of qualitative rapid HIV-1 and HIV-2 test kits....
...
Medicine Products: